Compound K attenuates hyperglycemia by enhancing glucagon-like peptide-1 secretion through activating TGR5 via the remodeling of gut microbiota and bile acid metabolism

BACKGROUND: Incretin impairment, characterized by insufficient secretion of L-cell-derived glucagon-like peptide-1 (GLP-1), is a defining step of type 2 diabetes mellitus (T2DM). Ginsenoside compound K (CK) can stimulate GLP-1 secretion; however, the potential mechanism underlying this effect has no...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Fengyuan, Huang, Shuo, Xu, Wangda, Chen, Lan, Su, Jianming, Ni, Haixiang, Feng, Xiaohong, Chen, Jie, Wang, Xi, Huang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597441/
https://www.ncbi.nlm.nih.gov/pubmed/36312739
http://dx.doi.org/10.1016/j.jgr.2022.03.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597441/
https://www.ncbi.nlm.nih.gov/pubmed/36312739
http://dx.doi.org/10.1016/j.jgr.2022.03.006

Ejemplares similares